Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Xspray Pharma AB ( (SE:XSPRAY) ) has shared an announcement.
Xspray Pharma AB has announced the composition of its Nomination Committee for the Annual General Meeting scheduled for May 12, 2026. The committee, formed according to the principles set in the previous AGM, will prepare proposals for the election of board members and other key positions. This announcement is part of Xspray’s ongoing corporate governance efforts, ensuring stakeholder involvement in the strategic direction of the company.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company specializing in developing improved versions of marketed protein kinase inhibitors (PKI) for cancer treatment. Utilizing its patented HyNap™ technology, the company aims to lead the oncology market segment with its innovative drug candidates, including Dasynoc®, which is under FDA review, and other optimized versions of existing cancer drugs.
Average Trading Volume: 153,560
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.13B
Find detailed analytics on XSPRAY stock on TipRanks’ Stock Analysis page.